{
  "source_pdf": "data/clinical_files/FlublokPI.pdf",
  "blocks": [
    {
      "id": "d3b426e1",
      "page_index": 0,
      "role": "List",
      "bbox": [
        1309.2274169921875,
        2011.5777587890625,
        2401.08642578125,
        3140.029296875
      ],
      "text": "5.3 Altered Immunocompetence\nIf Flublok is administeredtoimmunocompromisedindividuals, includingpersons receiving\nimmunosuppressive therapy, the immune response may be diminished.\n5.4 Limitations of Vaccine Effectiveness\nVaccination with Flublok may not protect all vaccine recipients.\n5.5 Syncope\nSyncope (fainting) has been reported following vaccination with Flublok. Procedures\nshould be in place to avoid injury from fainting.\n6\nADVERSE REACTIONS\nIn adults 18 through 49 years of age, the most common (≥10%) injection-site adverse\nreaction was pain (37%); the most common (≥10%) solicited systemic adverse reactions\nwere headache (15%), fatigue (15%) and muscle pain (11%). (6.1)\nIn adults 50 through 64 years of age, the most common (≥10%) injection site adverse\nreaction was pain (32%); the most common (≥10%) solicited systemic adverse reactions\nwere headache (17%), fatigue (13%), and muscle pain (11%). (6.1)\nIn adults 65 years of age and older, the most common (≥10%) injection site adverse\nreaction was pain (19%); the most common (≥10%) solicited systemic adverse reactions\nwere fatigue (13%) and headache (10%). (6.1)\n6.1 Clinical Trials Experience\nBecause clinical studies are conducted under widely varying conditions, adverse reaction\nrates observed in the clinical studies of a vaccine cannot be directly compared to rates\nin the clinical studies of another vaccine and may not reﬂect the rates observed in clinical\npractice.\nThe safety experience with Flublok Quadrivalent is relevant to Flublok because both\nvaccines are manufactured using the same process and have overlapping compositions.\nFlublok\nFlublok has been administered to and safety data collected from2497 adults 18 through\n49 years of age, 972 adults 50 through 64 years of age, and 1078 adults aged 65 years\nand older enrolled in ﬁve randomized, placebo- or active-controlled clinical trials. Clinical\nsafety data for Flublok are presented fromfour clinical trials (Studies 1, 2, 3, and 4). Data\nfrom a placebo-controlled trial in adults 18 through 49 years of age (Study 1) are\npresented, followed by data pooled according to age group fromStudies 2 and 4 (adults\n50 through 64 years of age) and Studies 3 and 4 (adults aged 65 years and older).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9600590467453003,
        "detection_dpi": 300
      }
    },
    {
      "id": "f2451c01",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        141.13783264160156,
        2827.9560546875,
        1231.593017578125,
        3137.365478515625
      ],
      "text": "g g\ng\nAppropriate medical treatment must be immediately available to manage potentia\nanaphylactic reactions following administration of Flublok.\n5.2 Guillain-Barré Syndrome\nIf GBS has occurred within 6 weeks of receipt of a prior inﬂuenza vaccine, the decision\ntogiveFlublokshouldbebasedoncareful considerationof thepotential beneﬁtsandrisks\nThe 1976 swine inﬂuenza vaccine was associated with an increased frequency of\nGuillain-BarréSyndrome(GBS). Evidenceforacausal relationof GBSwithotherinﬂuenza\nvaccines is inconclusive; if an excess risk exists, it is probably slightly more than one\nadditional case per 1 million persons vaccinated.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9716604351997375,
        "detection_dpi": 300
      }
    },
    {
      "id": "494ce5dc",
      "page_index": 0,
      "role": "Table",
      "bbox": [
        177.26646423339844,
        964.67724609375,
        2352.682861328125,
        1961.1851806640625
      ],
      "text": "[TABLE 3 - See table_p1_494ce5dc.png]",
      "html": null,
      "image_path": "figures/table_p1_494ce5dc.png",
      "metadata": {
        "score": 0.76356440782547,
        "detection_dpi": 300
      }
    },
    {
      "id": "ccb60f3d",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        145.55084228515625,
        2659.14111328125,
        1238.770263671875,
        2748.82275390625
      ],
      "text": "Do not administer Flublok to anyone with a history of severe allergic reactions (e.g.,\nanaphylaxis) to any component of the vaccine. [see Postmarketing Experience [6.2] and\nDescription (11)]",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9712105989456177,
        "detection_dpi": 300
      }
    },
    {
      "id": "e90dd663",
      "page_index": 0,
      "role": "List",
      "bbox": [
        1373.18115234375,
        367.4037170410156,
        2406.96142578125,
        745.040771484375
      ],
      "text": "• In adults 18 through 49 years of age, the most common (≥10%) injection-site\nadverse reaction was pain (37%); the most common (≥10%) solicited systemic\nadverse reactions were headache (15%), fatigue (15%) and muscle pain (11%).\n(6.1)\n• In adults 50 through 64 years of age, the most common (≥10%) injection site\nadverse reaction was pain (32%); the most common (≥10%) solicited systemic\nadverse reactions were headache (17%), fatigue (13%), and muscle pain (11%).\n(6.1)\n• In adults 65 years of age and older, the most common (≥10%) injection site\nadverse reaction was pain (19%); the most common (≥10%) solicited systemic\nadverse reactions were fatigue (13%) and headache (10%). (6.1)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9375213384628296,
        "detection_dpi": 300
      }
    },
    {
      "id": "c8e24671",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        149.14266967773438,
        456.2256164550781,
        1226.3074951171875,
        570.1927490234375
      ],
      "text": "INDICATIONS AND USAGE\nFlublok is a vaccine indicated for active immunization for the prevention of disease\ncaused by inﬂuenza A virus subtypes and inﬂuenza type B virus contained in the\nvaccine. Flublok is approved for use in persons 18 years of age and older. (1)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9515040516853333,
        "detection_dpi": 300
      }
    },
    {
      "id": "cf59de11",
      "page_index": 0,
      "role": "Title",
      "bbox": [
        1720.6051025390625,
        320.5289306640625,
        2029.243896484375,
        359.23077392578125
      ],
      "text": "ADVERSE REACTIONS",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9592512249946594,
        "detection_dpi": 300
      }
    },
    {
      "id": "4d9252a0",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        1390.61572265625,
        170.00759887695312,
        2409.17138671875,
        274.0050964355469
      ],
      "text": "If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior\ninﬂuenza vaccine, the decision to give Flublok should be based on careful\nconsideration of potential beneﬁts and risks. (5.2)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9480558633804321,
        "detection_dpi": 300
      }
    },
    {
      "id": "fbf97efa",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        151.17172241210938,
        2006.7503662109375,
        1240.503173828125,
        2269.609619140625
      ],
      "text": "FULL PRESCRIBING INFORMATION\n1\nINDICATIONS AND USAGE\nFlublokisavaccineindicatedfor activeimmunizationfor thepreventionof diseasecaused\nby inﬂuenzaAvirus subtypes and inﬂuenza type Bvirus contained in the vaccine. Flublok\nis approved for use in persons 18 years of age and older.\n2\nDOSAGE AND ADMINISTRATION\nFor intramuscular use.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9099435806274414,
        "detection_dpi": 300
      }
    },
    {
      "id": "cae7d0ff",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        1359.96337890625,
        910.1768798828125,
        2008.50439453125,
        955.4248657226562
      ],
      "text": "See 17 for PATIENT COUNSELING INFORMATION",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9076301455497742,
        "detection_dpi": 300
      }
    },
    {
      "id": "cc8db2ee",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        1352.1309814453125,
        778.5374755859375,
        2408.657958984375,
        885.5157470703125
      ],
      "text": "To report SUSPECTED ADVERSE REACTIONS, contact SanoﬁPasteur Inc., at\n(1-800-822-2463\n(1-800-Vaccine)\nor\nVAERS\nat\n1-800-822-7967\nor\nwww.vaers.hhs.gov.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8779281377792358,
        "detection_dpi": 300
      }
    },
    {
      "id": "40a53a79",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        159.8989715576172,
        2370.36083984375,
        1250.3929443359375,
        2519.569580078125
      ],
      "text": "Parenteral drug products should be inspected visually for particulate matter and discol-\noration prior to administration whenever solution and container permit. If either of these\nconditions exists, the vaccine should not be administered.\nGently invert the preﬁlled syringe prior to affixing a sterile needle.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8531858921051025,
        "detection_dpi": 300
      }
    },
    {
      "id": "0b9eba87",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        173.1505126953125,
        2570.46044921875,
        744.515625,
        2656.362548828125
      ],
      "text": "DOSAGE FORMS AND STRENGTHS\nlublok is an injection. A single dose is 0.5 mL.\nCONTRAINDICATIONS",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7071070671081543,
        "detection_dpi": 300
      }
    },
    {
      "id": "5db3d0ee",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        151.09356689453125,
        199.51824951171875,
        1184.6107177734375,
        378.1256408691406
      ],
      "text": "Thesehighlightsdonot includeall theinformationneededtouseFlublok®safel\nand effectively. See full prescribing information for Flublok.\nFlublok (Inﬂuenza Vaccine)\nInjection for Intramuscular Use 2024-2025 Formula\nI iti l US A\nl 2013",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.6768611669540405,
        "detection_dpi": 300
      }
    },
    {
      "id": "315e6ce9",
      "page_index": 1,
      "role": "List",
      "bbox": [
        145.49932861328125,
        185.06381225585938,
        1246.6885986328125,
        1256.531005859375
      ],
      "text": "Reactogenicity data froma small Phase 2 trial (Study 5) in adults 18 through 49 years of\nage, 153 of whom received Flublok 135mcg, are not presented. However, subjects from\nStudy 5 are included in the description of deaths and serious adverse events (SAEs). In\nall studies local (injectionsite) andsystemic adversereactions weresolicitedwiththeuse\nof a memory aid for 7 days following vaccination, and unsolicited adverse reactions were\ncollected for 28-30 days post-vaccination. In Studies 1- 3 and 5, SAEs were collected for\n6 months post-vaccination via clinic visit or telephone follow up on Day 28, telephone\nfollow up on Day 180, or by spontaneous reporting. Study 4 collected SAEs through 30\ndays following receipt of vaccine. Study 4 also actively solicited pre-speciﬁed common\nhypersensitivity-type reactions through 30 days following receipt of vaccine as a primary\nendpoint.\nStudy 1 (NCT00539981) included 4648 subjects 18 through 49 years of age for safety\nanalysis, randomized to receive Flublok (n=2344) or placebo (n=2304) (1) (see Clinical\nStudies [14.1]).\nStudy 2 (NCT00539864) included 602 subjects 50 through 64 years of age for safety\nanalysis, randomized to receive Flublok (n=300) or another U.S.-licensed trivalent\ninﬂuenza vaccine (Fluzone, manufactured by SanoﬁPasteur, Inc.) as an active control\n(n=302) (2).\nStudy 3 (NCT00395174) included 869 subjects aged 65 years and older for safety\nanalysis, randomized to receive Flublok (n=436) or another U.S.-licensed trivalent\ninﬂuenza vaccine (Fluzone) as an active control (n=433) (3).\nStudy 4 (NCT01825200) included 2627 subjects aged 50 years and older for safety\nanalysis, randomized to receive Flublok (n=1314) or another U.S.-licensed trivalent\ninﬂuenzavaccine(Aﬂuria, manufacturedbybioCSLPtyLtd.)asanactivecontrol (n=1313).\nAmong subjects 50 through 64 years of age, 672 received Flublok and 665 received\nAﬂuria. Among subjects aged 65 years and older, 642 received Flublok and 648 received\nAﬂuria.\nIn a clinical trial of adults 18-49 years of age (Study 1, Table 1) the mean age of\nparticipants was 32.5 years, 59% were female, and 67% were Caucasian (see Clinical\nStudies [14.1]).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9586350321769714,
        "detection_dpi": 300
      }
    },
    {
      "id": "e6ddf365",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        153.0273895263672,
        2272.70654296875,
        1242.8265380859375,
        2826.668701171875
      ],
      "text": "NOTE: Data based on the most severe response reported by subjects. Results ≥1%\nreported to nearest whole percent; results >0 but <1% reported as <1%.\n*Total VaccinatedCohort isdeﬁnedasall randomizedsubjectswhoreceivedstudyvaccine\naccording to the treatment actually received and who provided data.\n†Study 1 is registered as NCT00539981 under the National Clinical Trials registry.\n‡Denominators for Study 1: The total number of enrolled, randomized, and vaccinated\nsubjectswas2344intheFlublokgroupand2304intheplacebogroup. For all categories\nexcept fever, the number of subjects with missing values was 72 in the Flublok group\nand73inthePlacebogroupsothat thesedenominatorsare2272and2231respectively.\nFor fever, 89 Flublok recipients and 104 Placebo recipients were missing data, making\nthese denominators 2255 and 2200 respectively.\n§Moderate=hadit, andit was badenoughtoprevent asigniﬁcant part of usual activities;\nSevere = had it, and it prevented most or all of normal activities, or had to see a doctor\nfor prescription medicine.\n¶Fever deﬁned as ≥100.4°F (38°C). Mild (≥100.4° to <101.1°F); Moderate (≥101.2°F to\n<102.2°F); Severe (≥102.2°F)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9798182249069214,
        "detection_dpi": 300
      }
    },
    {
      "id": "de504429",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        190.1612091064453,
        1275.42822265625,
        1210.5843505859375,
        1383.2579345703125
      ],
      "text": "Table 1: Frequency of Solicited Local Injection Site Adverse Reactions and\nSystemic Adverse Reactions within 7 Days of Administration of Flublok or\nPlacebo in Adults 18-49 Years of Age, Study 1, Total Vaccinated Cohort*,†,‡",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9945058226585388,
        "detection_dpi": 300
      }
    },
    {
      "id": "8859d2a1",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1353.088623046875,
        1687.791259765625,
        2357.14892578125,
        1805.145751953125
      ],
      "text": "Table 3: Frequency of Solicited Local Injection Site Adverse Reactions and\nSystemic Adverse Reactions within 7 Days of Administration of Flublok or\nComparator in Adults ≥65 Years of Age, Studies 3 and 4, Total Vaccinated\nCohort *,†",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9862704873085022,
        "detection_dpi": 300
      }
    },
    {
      "id": "8ec09c43",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1352.033935546875,
        165.81150817871094,
        2348.456787109375,
        283.018798828125
      ],
      "text": "Table 2: Frequency of Solicited Local Injection Site Adverse Reactions and\nSystemic Adverse Reactions within 7 Days of Administration of Flublok or\nComparator in Adults 50-64 Years of Age, Studies 2 and 4, Total Vaccinated\nCohort*,†",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9769933819770813,
        "detection_dpi": 300
      }
    },
    {
      "id": "00919b71",
      "page_index": 1,
      "role": "Table",
      "bbox": [
        178.4370574951172,
        1405.2254638671875,
        1234.8115234375,
        2259.390869140625
      ],
      "text": "[TABLE 3 - See table_p2_00919b71.png]",
      "html": null,
      "image_path": "figures/table_p2_00919b71.png",
      "metadata": {
        "score": 0.8676624894142151,
        "detection_dpi": 300
      }
    },
    {
      "id": "7b85a376",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1308.2869873046875,
        1131.541259765625,
        2402.676513671875,
        1625.9193115234375
      ],
      "text": "NOTE: Data based on the most severe response reported by subjects. Results ≥1%\nreported to nearest whole percent; results >0 but <1% reported as <1%.\n*Total VaccinatedCohort isdeﬁnedasall randomizedsubjectswhoreceivedstudyvaccine\naccording to the treatment actually received and who provided data.\n†Pooled Data from Studies 2 and 4. For Studies 2 and 4, the U.S.-licensed IIV3\ncomparators were Fluzone and Aﬂuria, respectively. Studies 2 and 4 are registered as\nNCT00539864 and NCT01825200, respectively, under the National Clinical Trials\nregistry.\n‡Moderate=hadit, andit was badenoughtoprevent asigniﬁcant part of usual activities;\nSevere = had it, and it prevented most or all of normal activities, or had to see a doctor\nfor prescription medicine.\n§Fever deﬁned as ≥100.4°F (38°C). Mild (≥100.4° to <101.1°F); Moderate (≥101.2°F to\n<102.2°F); Severe(≥102.2°F) For fever, 12Flublokrecipientsand5IIV3recipientswere\nmissing data, making these denominators 964 and 962, respectively.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9027670621871948,
        "detection_dpi": 300
      }
    },
    {
      "id": "06f2cbea",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1316.0489501953125,
        2654.197998046875,
        2403.962646484375,
        2969.2119140625
      ],
      "text": "NOTE: Data based on the most severe response reported by subjects. Results ≥1%\nreported to nearest whole percent; results >0 but <1% reported as <1%.\n*Total VaccinatedCohort isdeﬁnedasall randomizedsubjectswhoreceivedstudyvaccine\naccording to the treatment actually received and who provided data.\n†Pooled Data from Studies 3 and 4. For Studies 3 and 4, the U.S.-licensed IIV3\ncomparators were Fluzone and Aﬂuria, respectively. Studies 3 and 4 are registered as\nNCT00395174 and NCT01825200, respectively, under the National Clinical Trials\nregistry.\n‡Moderate=hadit, andit was badenoughtoprevent asigniﬁcant part of usual activities;\nS\nh d i\nd i\nd\nll f\nl\ni i i\nh d\nd",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9128652215003967,
        "detection_dpi": 300
      }
    },
    {
      "id": "9b64a619",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        153.2301025390625,
        2865.389404296875,
        1235.7469482421875,
        3139.18408203125
      ],
      "text": "Across three clinical trials (Studies 2 – 4, Tables 2 and 3) a total of 2050 adults age 50\nyears and older received Flublok and 2048 received a U.S.-licensed trivalent inactivated\ninﬂuenza vaccine (IIV3) comparator. The mean age of Flublok study participants was 65\nyears; 56% were female and 80% were Caucasian.\nThe incidence of solicited reactogenicity differed between adults 50 through 64 years of\nage and adults aged 65 years and older. Therefore, data from Studies 2, 3, and 4 were\npooled according to age group and are presented separately (Tables 2 and 3).\nMost adverse reactions in both age groups were mild in severity.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8395281434059143,
        "detection_dpi": 300
      }
    },
    {
      "id": "b04849d6",
      "page_index": 1,
      "role": "Table",
      "bbox": [
        1319.685546875,
        1821.250732421875,
        2404.30810546875,
        2653.081787109375
      ],
      "text": "[TABLE 10 - See table_p2_b04849d6.png]",
      "html": null,
      "image_path": "figures/table_p2_b04849d6.png",
      "metadata": {
        "score": 0.7599875926971436,
        "detection_dpi": 300
      }
    },
    {
      "id": "b9ff4cd3",
      "page_index": 1,
      "role": "Table",
      "bbox": [
        1336.7303466796875,
        306.3638610839844,
        2398.6123046875,
        1121.3643798828125
      ],
      "text": "[TABLE 7 - See table_p2_b9ff4cd3.png]",
      "html": null,
      "image_path": "figures/table_p2_b9ff4cd3.png",
      "metadata": {
        "score": 0.7239257097244263,
        "detection_dpi": 300
      }
    },
    {
      "id": "ee612e03",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1372.17578125,
        3033.96728515625,
        2372.54736328125,
        3102.544189453125
      ],
      "text": "ver deﬁned as ≥100.4°F (38°C). Mild (≥100.4° to <101.1°F); Moderate (≥101.2°F\n02.2°F); Severe (≥102.2°F)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.5340326428413391,
        "detection_dpi": 300
      }
    },
    {
      "id": "cde88a82",
      "page_index": 2,
      "role": "List",
      "bbox": [
        142.3849334716797,
        242.7105712890625,
        1262.179931640625,
        2092.05615234375
      ],
      "text": "placebo recipient. Both deaths occurred more than 28 days following vaccination and\nneither was consideredvaccine-related. SAEs werereportedby 32Flublok recipients and\n35 placebo recipients. One SAE in a Flublok recipient was assessed as possibly related\nto the vaccine: pleuropericarditis with effusions requiring hospitalization and drainage. No\nspeciﬁc cause was identiﬁed. The patient recovered.\nAmong adults 50-64 years of age (Studies 2 and 4 pooled), through up to 6 months or\n30days, post- vaccination, respectively, therewerenodeaths; SAEs werereportedby 10\nsubjects, 6 Flublok recipients and 4 IIV3 recipients. One of the SAEs, vasovagal syncope\nfollowing injection of Flublok, was considered related to administration of study vaccine.\nAmongadults65yearsof ageandolder (Studies3and4pooled), throughupto6months\nor 30days post-vaccination, respectively, therewere4deaths, 2inFlublok recipients and\n2 in IIV3 recipients. None were considered related to the study vaccines. SAEs were\nreported from 80 subjects, 37 Flublok recipients, 43 in IIV3 recipients. No SAEs were\nconsidered related to the study vaccines.\nIn Study 1 (adults 18-49 years of age), the most frequent unsolicited adverse events,\noccurring in 1%-2% of subjects, were nasopharyngitis, upper respiratory infection,\nheadache, cough, nasal congestion, pharyngolaryngeal pain, and rhinorrhea.\nAmong adults 50-64 years of age (Studies 2 and 4 pooled), the most frequent unsolicited\nadverseevents, occurringin1%of subjects, werediarrheaandcough.Amongadults≥65\nyears of age (Studies 3 and 4 pooled), the most frequent unsolicited adverse events,\noccurring in 1% of subjects, were nasopharyngitis and cough.\nAmong adults 50 years of age and older (Study 4) for whom the incidence of rash,\nurticaria, swelling, non- pitting edema, or other potential hypersensitivity reactions were\nactivelysolicitedfor 30daysfollowingvaccination, atotal of 2.4%of Flublokrecipientsand\n1.6%of IIV3 recipients reported such events over the 30 day follow-up period. Atotal of\n1.9%and 0.9%of Flublok and IIV3 recipients, respectively, reported these events in the\n7days followingvaccination. Of thesesolicitedevents, rashwas most frequently reported\n(Flublok 1.3%, IIV3 0.8%) over the 30 day follow-up period.\nFlublok Quadrivalent\nFlublokQuadrivalent hasbeenadministeredtoandsafetydatacollectedfrom4328adults\n50 years of age and older (Study 61) and 998 adults 18-49 years of age (Study 72).\nSAEs were collected for 6 months post-vaccination via clinic visit or remote contact.\nStudy 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to\nreceive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by\nGlaxoSmithKline) as an active control [see Clinical Studies (14.1)]. The safety analysis\npopulation included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine\nrecipients. The mean age of participants was 62.7 years. Overall, 58%of subjects were\nfemale, 80% white/Caucasian, 18% black/African American, 0.9% American Indian/\nAlaskan Native, 0.4% Asian, 0.2% Native Hawaiian/Paciﬁc Islander, 0.7% other racial\ngroups, and 5% of Hispanic/Latino ethnicity.\nAmongadults50yearsof ageandolder (Study6), therewerenoSAEsconsideredrelated\nto study vaccine.\nStudy 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to\nreceive Flublok Quadrivalent or a Comparator inactivated inﬂuenza vaccine (Fluarix®\nQuadrivalent, manufacturedby GlaxoSmithKline). Thesafety analysis populationincluded\n998recipients of Flublok Quadrivalent and332Comparator vaccinerecipients. Themean\nage of participants was 33.5 years. Overall, 65% of subjects were female, 59%\nwhite/Caucasian, 37% black/African American, 1.0% Native Hawaiian/Paciﬁc Islander,\n0.8%American Indian/Alaskan Native, 0.5%Asian, 1.4%other racial groups, and 16%of\nHispanic/Latino ethnicity.\nAmongadults18-49yearsof age(Study7), through6monthspost-vaccination, therewere\nno SAEs considered related to study vaccine.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8222869634628296,
        "detection_dpi": 300
      }
    },
    {
      "id": "8bfffcba",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1320.5130615234375,
        2769.51513671875,
        2392.76611328125,
        3137.634033203125
      ],
      "text": ") ( )\nStudy 1 enrolled and vaccinated 4648 healthy adults (mean age 32.5 years) randomized\nn a 1:1 ratio to receive a single dose of Flublok (n=2344) or saline placebo (n=2304).\nAmong enrolled subjects, 59%were female, 67%were white, 19%African-American, 2%\nAsian, < 1%otherraces, and11%of Latino/Hispanicethnicity. Culture-conﬁrmedinﬂuenza\nwas assessed by active and passive surveillance for inﬂuenza-like illness (ILI) beginning\n2 weeks post-vaccination until the end of the inﬂuenza season, approximately 7 months\npost- vaccination. ILI was deﬁned as having at least 2 of 3 symptoms (no speciﬁed\nduration) in the following categories: 1) fever ≥100°F; 2) respiratory symptoms (cough,\nsore throat, or runny nose/stuffy nose); or 3) systemic symptoms (myalgias, arthralgias,\nheadache, chills/sweats, or tiredness/malaise). For subjects with an episode of ILI, nasa\nand throat swab samples were collected for viral culture.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9868848323822021,
        "detection_dpi": 300
      }
    },
    {
      "id": "e6a92ee4",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        153.22572326660156,
        2228.769287109375,
        1252.9244384765625,
        2514.0263671875
      ],
      "text": "6.2 Postmarketing Experience\nThe following events have been spontaneously reported during post approval use of\nFlublok or Flublok Quadrivalent. They aredescribedbecauseof thetemporal relationship,\nthe biologic plausibility for a causal relationship to Flublok or Flublok Quadrivalent, and\ntheir potential seriousness. Because these events are reported voluntarily from a\npopulation of uncertain size, it is not always possible to reliably estimate their frequency\nor establish a causal relationship to vaccine exposure.\nImmune system disorders: anaphylaxis, allergic reactions, and other forms of hypersen-\nsitivity (including urticaria).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9860596060752869,
        "detection_dpi": 300
      }
    },
    {
      "id": "e8bb5c53",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1314.709716796875,
        862.9839477539062,
        2400.187255859375,
        1069.4017333984375
      ],
      "text": "Data froma randomized, controlled trial demonstrated that children 6 months to less than\n3 years of age had diminished hemagglutinin inhibition (HI) responses to Flublok\ncomparedtoaU.S.-licensedinﬂuenzavaccineapprovedforuseinthispopulation, strongly\nsuggestingthat Flublok wouldnot beeffectiveinchildrenyounger than3years of age(6).\nSafety and effectiveness of Flublok have not been established in children 3 years to less\nthan 18 years of age.\nG",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.98398756980896,
        "detection_dpi": 300
      }
    },
    {
      "id": "731acc01",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1310.5291748046875,
        2099.236083984375,
        2398.034912109375,
        2414.86669921875
      ],
      "text": "Flublok contains recombinant HAproteins of the three strains of inﬂuenza virus speciﬁed\nby health authorities for inclusion in the annual seasonal vaccine. These proteins function\nas antigens which induce a humoral immune response, measured by hemagglutination\ninhibition (HI) antibody).\nAntibodies against one inﬂuenza virus type or subtype confer limited or no protection\nagainst another. Furthermore, antibodies to one antigenic variant of inﬂuenza virus might\nnot protect against a new antigenic variant of the same type or subtype. Frequent\ndevelopment of antigenicvariantsthroughantigenicdrift isthevirologicbasisfor seasonal\nepidemicsandthereasonfor theusual replacement of oneor moreinﬂuenzavirusstrains\nin each year’s inﬂuenza vaccine",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.969664454460144,
        "detection_dpi": 300
      }
    },
    {
      "id": "29a600b2",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1317.878173828125,
        1097.4771728515625,
        2396.459228515625,
        1292.057373046875
      ],
      "text": "Data froman efficacy study (Study 6), which included 1759 subjects ≥65 years and 525\nsubjects ≥75 years who received Flublok Quadrivalent, are insufficient to determine\nwhether elderly subjects respond differently from younger subjects (See Clinical Studies\n[14]). Data for Flublok Quadrivalent are relevant to Flublok because both vaccines are\nmanufactured using the same process and have overlapping compositions.\n11\nDESCRIPTION",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9824763536453247,
        "detection_dpi": 300
      }
    },
    {
      "id": "9ba3efea",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1326.9912109375,
        1633.6510009765625,
        2402.520263671875,
        1775.050537109375
      ],
      "text": "Flublok is standardized according to United States Public Health Service (USPHS)\nequirements. For the2024-2025inﬂuenzaseasonit is formulatedtocontain135mcgHA\ner 0.5mLdose, with45mcgHAof eachof thefollowing3inﬂuenzavirusstrains:A/West\nVirginia/30/2022 (A/Wisconsin/67/2022 pdm09-like virus) (H1N1), A/Massachusetts/18/\n022 (H3N2) and B/Austria/1359417/2021",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9853274822235107,
        "detection_dpi": 300
      }
    },
    {
      "id": "a474ff8b",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1314.791259765625,
        1294.0223388671875,
        2399.25244140625,
        1611.1226806640625
      ],
      "text": "SC\nO\nFlublok [Inﬂuenza Vaccine] is a sterile, clear, colorless injection containing recombinant\nhemagglutinin(HA) proteinsfromthreeinﬂuenzavirusesfor intramuscular use. It contains\npuriﬁedHAproteins producedinacontinuous insect cell line(expresSF+®) that is derived\nfrom Sf9 cells of the fall armyworm, Spodoptera frugiperda (which is related to moths,\ncaterpillars and butterﬂies), and grown in serum-free medium composed of chemically-\ndeﬁned lipids, vitamins, amino acids, and mineral salts. Each of the three HAs is\nexpressed in this cell line using a baculovirus vector (Autographa californica nuclear\npolyhedrosis virus), extracted from the cells with Triton X-100 and further puriﬁed by\ncolumn chromatography. The puriﬁed HAs are then blended and ﬁlled into single-dose\nsyringes",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9613624215126038,
        "detection_dpi": 300
      }
    },
    {
      "id": "eb77b8c4",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1317.2069091796875,
        632.8298950195312,
        2395.478759765625,
        851.1441650390625
      ],
      "text": "y\nIt isnot knownwhether Flublokisexcretedinhumanmilk. Dataarenot availabletoassess\nthe effects of Flublok on the breastfed infant or on milk production/excretion.\nThe developmental and health beneﬁts of breastfeeding should be considered along with\nthe mother’s clinical need for Flublok and any potential adverse effects on the breastfed\nchild fromFlublok or fromthe underlying maternal condition. For preventive vaccines, the\nunderlying condition is susceptibility to disease prevented by the vaccine.\n84 Pediatric Use",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9669063687324524,
        "detection_dpi": 300
      }
    },
    {
      "id": "8c9fce6c",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1331.33935546875,
        2642.8154296875,
        2392.41650390625,
        2744.802978515625
      ],
      "text": "he efficacy of Flublok in protecting against culture-conﬁrmed inﬂuenza illness was\nvaluated in a randomized, observer-blind, placebo-controlled multicenter trial conducted\nn the U.S. during the 2007-2008 inﬂuenza season in adults 18-49 years of age (Study\n) (1)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9621705412864685,
        "detection_dpi": 300
      }
    },
    {
      "id": "4a2cc2cd",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1318.6427001953125,
        395.25091552734375,
        2394.83984375,
        574.6171875
      ],
      "text": "Animal\nn a developmental toxicity study, female rats were administered Flublok by intramuscular\nnjectiontwiceprior tomating(35days and14days prior tomating) andongestationDay\n6. The total dose was 0.5 mL (divided) on each occasion (a human dose is 0.5 mL). No\nvaccine-related fetal malformations or variations and no adverse effects on pre-weaning\ndevelopment or female fertility were observed in the study.\n82 L\nt ti",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.953013002872467,
        "detection_dpi": 300
      }
    },
    {
      "id": "ce3afa55",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        163.9864044189453,
        2869.10400390625,
        1233.1094970703125,
        3146.10107421875
      ],
      "text": "All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S.\ngeneral population, theestimatedbackgroundrisks of major birthdefects andmiscarriage\nnclinicallyrecognizedpregnanciesare2%to4%and15%to20%, respectively.Available\ndataonFlublokandFlublokQuadrivalent administeredtopregnant womenarelimitedand\nnsufficient to inform vaccine-associated risks in pregnant women.\nA developmental study of Flublok has been performed in rats administered 0.5 mL\ndivided, a single human dose is 0.5 mL) of Flublok prior to mating and during gestation.\nThis study revealed no evidence of harm to the fetus due to Flublok (see Data).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9371795654296875,
        "detection_dpi": 300
      }
    },
    {
      "id": "42287345",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        166.7902069091797,
        2517.41455078125,
        1220.64794921875,
        2600.35595703125
      ],
      "text": "Nervous system disorders: facial palsy (Bell’s palsy), Guillain-Barré syndrome, syncope\nUSE IN SPECIFIC POPULATIONS\n1 Pregnancy",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9441726803779602,
        "detection_dpi": 300
      }
    },
    {
      "id": "ff185924",
      "page_index": 2,
      "role": "Title",
      "bbox": [
        160.14210510253906,
        2117.481201171875,
        341.65411376953125,
        2157.057373046875
      ],
      "text": "NCT02285998",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9346354007720947,
        "detection_dpi": 300
      }
    },
    {
      "id": "f15d4738",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1324.3646240234375,
        1800.116455078125,
        2396.046630859375,
        2059.892578125
      ],
      "text": "A single 0.5 mL dose of Flublok contains sodium chloride (4.4 mg), monobasic sodium\nphosphate (0.2 mg), dibasic sodiumphosphate (0.5 mg), and polysorbate 20 (Tween®20)\n27.5mcg). Each0.5mLdoseof Flublokmayalsocontainresidual amountsof baculovirus\nandSpodopterafrugiperdacell proteins (≤14.3mcg), baculovirus andcellular DNA(≤10\nng), and Triton X-100 (≤100 mcg).\nFlublok contains no egg proteins, antibiotics, or preservatives. The single-dose, preﬁlled\nsyringes contain no natural rubber latex.\n2\nCLINICAL PHARMACOLOGY",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8698462843894958,
        "detection_dpi": 300
      }
    },
    {
      "id": "2670d42a",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1301.5499267578125,
        213.65834045410156,
        2395.159423828125,
        368.6438293457031
      ],
      "text": "Disease-associated Maternal and/or Embryo/Fetal Risk\nPregnant womenareat increasedriskof complicationsassociatedwithinﬂuenzainfection\ncompared to non-pregnant women. Pregnant women with inﬂuenza may be at increased\nrisk for adverse pregnancy outcomes, including preterm labor and delivery.\nData",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8683024048805237,
        "detection_dpi": 300
      }
    },
    {
      "id": "5e0b8c17",
      "page_index": 2,
      "role": "Title",
      "bbox": [
        158.9113006591797,
        2166.658935546875,
        344.710205078125,
        2205.53271484375
      ],
      "text": "2NCT02290509",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8075494170188904,
        "detection_dpi": 300
      }
    },
    {
      "id": "b97e281e",
      "page_index": 2,
      "role": "Title",
      "bbox": [
        1312.5223388671875,
        2602.168701171875,
        2034.9588623046875,
        2634.097900390625
      ],
      "text": "14.1 Efficacy Against Laboratory-Conﬁrmed Inﬂuenza",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7239204049110413,
        "detection_dpi": 300
      }
    },
    {
      "id": "ee756d42",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        148.1519775390625,
        2731.349853515625,
        1232.1741943359375,
        2808.507568359375
      ],
      "text": "Healthcare providers are encouraged to enroll women who receive Flublok during\npregnancy in SanoﬁPasteur Inc.’s vaccination pregnancy registry by calling 1-800-822-\n2463",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.6349073648452759,
        "detection_dpi": 300
      }
    },
    {
      "id": "39e5077b",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1297.0526123046875,
        2461.61279296875,
        2343.65673828125,
        2596.819580078125
      ],
      "text": "13\nNONCLINICAL TOXICOLOGY\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\nFlublok has not been evaluated for carcinogenic or mutagenic potential, or for impairm\nof male fertility in animals.\n14\nCLINICAL STUDIES",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.578911304473877,
        "detection_dpi": 300
      }
    },
    {
      "id": "e218b58f",
      "page_index": 2,
      "role": "Title",
      "bbox": [
        1311.840576171875,
        167.84671020507812,
        1597.4881591796875,
        205.4418487548828
      ],
      "text": "Clinical Considerations\nDi\ni\nd M",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.5620818734169006,
        "detection_dpi": 300
      }
    },
    {
      "id": "a90fd2ca",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        168.13946533203125,
        2298.617431640625,
        1233.513427734375,
        2905.7939453125
      ],
      "text": "[\n])\nStudy 6 evaluated the efficacy of Flublok Quadrivalent in a randomized, observer-blind,\nctive-controlled, multi-center trial conducted during the 2014-2015 inﬂuenza season in\ndults 50 years of age and older. Atotal of 8963 healthy, medically stable adults (mean\nge 62.5 years) were randomized in a 1:1 ratio to receive a single dose of Flublok\nQuadrivalent (n=4474) or a U.S.-licensed quadrivalent inactivated inﬂuenza vaccine\nComparator, Fluarix Quadrivalent, manufactured by Glaxo SmithKline) (n=4489).\nAmong randomized subjects, 58%were female, 80%white, 18%black/African-American,\n%other races, and 5%of Hispanic/Latino ethnicity. Atotal of 5186 (60%) subjects were\n0-64 years of age and 3486 (40%) were ≥65 years of age. Real-time polymerase chain\neaction(rtPCR) -conﬁrmedinﬂuenzawasassessedbyactiveandpassivesurveillancefor\nnﬂuenza-likeillness(ILI)beginning2weekspost-vaccinationuntil theendof theinﬂuenza\neason, approximately 6months post- vaccination. ILI was deﬁnedas havingat least one\nymptom (no speciﬁed duration) in each of two categories of respiratory and systemic\nymptoms. Respiratory symptoms included sore throat, cough, sputum production,\nwheezinganddifficultybreathing. Systemicsymptomsincludedfever > 99°F(>37°C) oral,\nhills, fatigue, headache and myalgia. For subjects with an episode of ILI, a nasopha-\nyngeal swab sample was collected for rtPCR testing and reﬂex viral culture of rtPCR-\nositive samples.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9948762059211731,
        "detection_dpi": 300
      }
    },
    {
      "id": "2def875b",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        158.29510498046875,
        399.677734375,
        1227.2462158203125,
        684.3984375
      ],
      "text": "(\n)\nThe pre-deﬁned success criterion for the primary efficacy analysis was that the lowe\nbound of the 95%conﬁdence interval (CI) of VEshould be at least 40%. Vaccine efficacy\nagainst antigenically matched culture-conﬁrmed CDC-ILI could not be determined reliably\nbecause 96% of the inﬂuenza isolates obtained from subjects in Study 1 were no\nantigenically matched to the strains represented in the vaccine. An exploratory analysis\nof VE of Flublok against all strains, regardless of antigenic match, isolated from any\nsubject with an ILI, not necessarily meeting CDC- ILI criteria, demonstrated an efficacy\nestimate of 44.8% (95% CI 24.4, 60.0). See Table 4 for a presentation of VE by case\ndeﬁnition and antigenic similarity",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9870612621307373,
        "detection_dpi": 300
      }
    },
    {
      "id": "ee98a145",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        162.07986450195312,
        2909.501953125,
        1239.927001953125,
        3136.1982421875
      ],
      "text": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol-deﬁned ILI due to\nany strain of inﬂuenza. Attack rates and relative vaccine efficacy (rVE), deﬁned as 1 –\nAttack rate Flublok Quadrivalent/ Attack Rate Comparator], were calculated for the total\nefficacy population (n=8604) for the primary efficacy endpoint and for several alternative\nefficacy endpoints (Table 5). Antigenic and phylogenetic evaluations of the similarity\n″matching″) of clinical isolates to vaccine antigens were not performed. CDC epidemio-\nogical data for the 2014-2015 inﬂuenza season indicated that InﬂuenzaA(H3N2) viruses",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.990221381187439,
        "detection_dpi": 300
      }
    },
    {
      "id": "51e95394",
      "page_index": 3,
      "role": "Figure",
      "bbox": [
        1336.7291259765625,
        392.9314270019531,
        2383.900634765625,
        1014.5637817382812
      ],
      "text": "[FIGURE 10 - See figure_p4_51e95394.png]",
      "html": null,
      "image_path": "figures/figure_p4_51e95394.png",
      "metadata": {
        "score": 0.9451068639755249,
        "detection_dpi": 300
      }
    },
    {
      "id": "e8cdbc7a",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        149.92742919921875,
        170.45721435546875,
        1237.2119140625,
        391.4334716796875
      ],
      "text": "The primary efficacy endpoint of Study 1 was Centers for Disease Control-deﬁned\ninﬂuenza-like illness (CDC-ILI) with a positive culture for an inﬂuenza virus strain\nantigenically resembling a strain represented in Flublok. CDC-ILI is deﬁned as fever of\n≥100°F oral accompanied by cough, sore throat, or both on the same day or on\nconsecutive days. Attack rates and vaccine efficacy (VE), deﬁned as the reduction in the\ninﬂuenzarateforFlublokrelativetoplacebo,werecalculatedforthetotal vaccinatedcohort\n(n=4648)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9855533242225647,
        "detection_dpi": 300
      }
    },
    {
      "id": "784ae2c2",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        1343.143310546875,
        263.92431640625,
        2362.77294921875,
        391.33282470703125
      ],
      "text": "Table 5: Relative Vaccine Efficacy (rVE) of Flublok Quadrivalent versus\nComparator against Laboratory-Conﬁrmed Inﬂuenza, Regardless of Antigenic\nSimilarity to Vaccine Antigens, Adults 50 Years of Age and Older, Study 6\n(Efficacy Population)*,†",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9801135063171387,
        "detection_dpi": 300
      }
    },
    {
      "id": "1aa3a054",
      "page_index": 3,
      "role": "List",
      "bbox": [
        1318.5457763671875,
        1729.3660888671875,
        2404.44287109375,
        2582.547119140625
      ],
      "text": "15\nREFERENCES\n1. Treanor JJ, El Sahly HM, King J, et. al. Protective efficacy of a trivalent recombinant\nhemagglutininproteinvaccine(FluBlok) against inﬂuenzainhealthyadults: arandomized,\nplacebo-controlled trial. Vaccine. 2011, Vol. 29, pp. 7733-7739.\n2. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and\nmmunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin\nnﬂuenza vaccine administered intramuscularly to healthy adults 50-64 years of age.\nVaccine. 2011, Vol. 29, pp. 2272-2278.\n3. Keitel WA, Treanor JJ, El Sahly HM, et.al. Comparative immunogenicity of recom-\nbinant inﬂuenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among\npersons ≥65 years old. Vaccine. 2009, Vol. 28, pp. 379-385.\n4. Izikson R, Leffell DJ, Bock SA, et. al. Randomized comparison of the safety of\nFlublok®versus licensed inactivated inﬂuenza vaccine in healthy, medically stable adults\n≥50years of age. Vaccine. 2015, Vol. 33, pp. 6622–6628.\n5. TreanorJJ, Schiff GM, HaydenFG, et.al. Safetyandimmunogenicityof abaculovirus-\nexpressed hemagglutinin inﬂuenza vaccine: a randomized controlled trial. JAMA. 2007,\nVol. 297, pp. 1577-1582.\n6. King JC, Cox MMJ, Reisinger K, et. al. Evaluation of the safety, reactogenicity and\nmmunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin\nnﬂuenza vaccine administered intramuscularly to healthy children aged 6-59 months.\nVaccine. 2009, Vol. 27, pp. 6589-6594.\n7. CBER/FDA. Guidance for Industry: Clinical Data Needed to Support the Licensure of\nSeasonal Inactivated Inﬂuenza Vaccines. s.l. : DHHS/CBER/FDA, 2007.\n16\nHOW SUPPLIED/STORAGE AND HANDLING\n16.1 How Supplied\nFlublok is supplied as a single-dose, 0.5 mL preﬁlled syringe in a 10 syringe carton.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8923411965370178,
        "detection_dpi": 300
      }
    },
    {
      "id": "81e6ae2b",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        1318.7320556640625,
        1015.88037109375,
        2396.154052734375,
        1291.7283935546875
      ],
      "text": "Abbreviations: rtPCR=reversetranscriptasepolymerasechainreaction; Comparator=U.S.-\nicensedquadrivalent inactivatedinﬂuenzavaccine, FluarixQuadrivalent, manufacturedby\nGlaxoSmithKline; n=number of inﬂuenzacases; N=number of subjectsintreatment group;\nRR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) × 100].\n*Study 6 is registered as NCT02285998.\n†Efficacy Population included all randomized subjects who received study vaccine and\nprovidedanyfollow-updocumentationfor inﬂuenza-likeillnessbeginningat least 14days\npost-vaccination. Excluded subjects with protocol deviations that could adversely affect\nffi",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9544553756713867,
        "detection_dpi": 300
      }
    },
    {
      "id": "e0ce1d25",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        199.23504638671875,
        733.29248046875,
        1181.364501953125,
        802.2220458984375
      ],
      "text": "Table 4: Vaccine Efficacy Against Culture-Conﬁrmed Inﬂuenza in Healthy\nAdults 18-49 Years of Age, Study 1*",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9316760301589966,
        "detection_dpi": 300
      }
    },
    {
      "id": "589d0c0c",
      "page_index": 3,
      "role": "Table",
      "bbox": [
        1321.953125,
        2655.116943359375,
        2394.046142578125,
        3123.06640625
      ],
      "text": "[TABLE 14 - See table_p4_589d0c0c.png]",
      "html": null,
      "image_path": "figures/table_p4_589d0c0c.png",
      "metadata": {
        "score": 0.8733048439025879,
        "detection_dpi": 300
      }
    },
    {
      "id": "2b801d7d",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        155.60189819335938,
        2197.383056640625,
        1234.290283203125,
        2276.64990234375
      ],
      "text": "The efficacy of Flublok Quadrivalent is relevant to Flublok because both vaccines are\nmanufactured using the same process and have overlapping compositions (see Descrip-\ntion [11])",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9091412425041199,
        "detection_dpi": 300
      }
    },
    {
      "id": "cd0259a0",
      "page_index": 3,
      "role": "List",
      "bbox": [
        162.2661590576172,
        1729.77880859375,
        1244.43505859375,
        2148.31787109375
      ],
      "text": "In Study 1 (NCT00539981) vaccine efficacy analyses were conducted on the Total\nVaccinatedCohort (all randomizedsubjects whoreceivedstudy vaccineaccordingtothe\ntreatment actually received and who provided data). Vaccine efficacy (VE) = 1 minus the\nratio of Flublok/placebo infection rates.\n†Determinedunder theassumptionof Poissonevent rates, accordingtoBreslowandDay,\n1987.\n‡MeetsCDCinﬂuenza-likeillness(CDC-ILI) deﬁnedasfever of ≥100°Foral accompanied\nby cough and/or sore throat, on the same day or on consecutive days.\n§Primary endpoint of trial.\n¶All culture-conﬁrmed cases are considered, regardless of whether they qualiﬁed as\nCDC-ILI.\n#Secondary endpoint of trial.\nÞExploratory (prespeciﬁed) endpoint of trial",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.862545907497406,
        "detection_dpi": 300
      }
    },
    {
      "id": "1de21691",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        1314.232421875,
        167.92352294921875,
        2383.29736328125,
        238.06112670898438
      ],
      "text": "predominated and that most inﬂuenzaA/H3N2 viruses were antigenically dissimilar whil\nA/H1N1 and B viruses were antigenically similar to vaccine antigens.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8909356594085693,
        "detection_dpi": 300
      }
    },
    {
      "id": "98b1e8e8",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        1402.1171875,
        1653.60693359375,
        2133.318359375,
        1687.3585205078125
      ],
      "text": "e of rtPCR-positive samples was performed in MDCK cells",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.5098204016685486,
        "detection_dpi": 300
      }
    },
    {
      "id": "23e695b9",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        144.08213806152344,
        685.9114379882812,
        1193.099853515625,
        725.8436889648438
      ],
      "text": "Manufactured by Protein Sciences Corporation (Meriden, CT) U.S. license No. 1795",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9661152958869934,
        "detection_dpi": 300
      }
    },
    {
      "id": "fcd511bb",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        149.08624267578125,
        837.978271484375,
        974.73193359375,
        874.8689575195312
      ],
      "text": "Flublok is a registered trademark of Protein Sciences Corporation.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9509007930755615,
        "detection_dpi": 300
      }
    },
    {
      "id": "09b06a41",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        153.20384216308594,
        314.59539794921875,
        1242.6302490234375,
        648.2970581054688
      ],
      "text": "Instruct the vaccine recipient to report any adverse events to their healthcare provider\nand/or to the Vaccine Adverse Event Reporting System (VAERS).\nProvide the vaccine recipient with the Vaccine Information Statements which are required\nby the National Childhood Vaccine Injury Act of 1986 to be given prior to vaccination.\nThese materials are available free of charge at the Centers for Disease Control (CDC)\nwebsite (www.cdc.gov/vaccines).\nEncourage women who receive Flublok while pregnant to notify SanoﬁPasteur Inc.\nsanoﬁpasteurpregnancyregistry.com or by calling 1-800-822-2463 (1-800-VACCINE).\nInstruct thevaccinerecipient that annual vaccinationtoprevent inﬂuenzaisrecommended.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8706106543540955,
        "detection_dpi": 300
      }
    },
    {
      "id": "b6adf62f",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        173.82167053222656,
        173.00613403320312,
        1241.9366455078125,
        296.0444030761719
      ],
      "text": "• Flublok contains non-infectious proteins that cannot cause inﬂuenza.\n• Flublokstimulatestheimmunesystemtoproduceantibodiesthat helpprotect against\ninﬂuenza viruses contained in the vaccine but does not prevent other respiratory\ninfections",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8700830340385437,
        "detection_dpi": 300
      }
    },
    {
      "id": "0aa9b86a",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        151.18377685546875,
        910.6110229492188,
        437.78875732421875,
        949.0458984375
      ],
      "text": "INFB4-FPLR-SL-JUL24",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7776336669921875,
        "detection_dpi": 300
      }
    },
    {
      "id": "c534e0f2",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        152.92013549804688,
        761.865966796875,
        567.4251708984375,
        800.2079467773438
      ],
      "text": "Distributed by SanoﬁPasteur Inc.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7632640600204468,
        "detection_dpi": 300
      }
    }
  ],
  "metadata": {
    "detection_dpi": 300,
    "total_pages": 5,
    "merge_settings": {
      "merge_overlapping": true,
      "merge_threshold": 0.1,
      "confidence_weight": 0.7,
      "area_weight": 0.3
    },
    "extraction": {
      "text_blocks": 61,
      "figure_blocks": 6,
      "figures_dir": "/Users/saul/projects/solstice/solstice/data/cache/FlublokPI/extracted/figures"
    }
  },
  "reading_order": [
    [
      "5db3d0ee",
      "c8e24671",
      "494ce5dc",
      "fbf97efa",
      "40a53a79",
      "0b9eba87",
      "ccb60f3d",
      "f2451c01",
      "4d9252a0",
      "cf59de11",
      "e90dd663",
      "cc8db2ee",
      "cae7d0ff",
      "d3b426e1"
    ],
    [
      "315e6ce9",
      "de504429",
      "00919b71",
      "e6ddf365",
      "9b64a619",
      "8ec09c43",
      "b9ff4cd3",
      "7b85a376",
      "8859d2a1",
      "b04849d6",
      "06f2cbea",
      "ee612e03"
    ],
    [
      "cde88a82",
      "ff185924",
      "5e0b8c17",
      "e6a92ee4",
      "42287345",
      "ee756d42",
      "ce3afa55",
      "e218b58f",
      "2670d42a",
      "4a2cc2cd",
      "eb77b8c4",
      "e8bb5c53",
      "29a600b2",
      "a474ff8b",
      "9ba3efea",
      "f15d4738",
      "731acc01",
      "39e5077b",
      "b97e281e",
      "8c9fce6c",
      "8bfffcba"
    ],
    [
      "e8cdbc7a",
      "2def875b",
      "e0ce1d25",
      "cd0259a0",
      "2b801d7d",
      "a90fd2ca",
      "ee98a145",
      "1de21691",
      "784ae2c2",
      "51e95394",
      "81e6ae2b",
      "98b1e8e8",
      "1aa3a054",
      "589d0c0c"
    ],
    [
      "b6adf62f",
      "09b06a41",
      "23e695b9",
      "c534e0f2",
      "fcd511bb",
      "0aa9b86a"
    ]
  ]
}